Investigational drug · Phase 2
DISC-0974
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "DISC-0974"
First trial start
2022
Jun 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DISC-0974", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anemia
- Inflammatory Bowel Disease (IBD)
- Inflammatory Bowel Disease (IBD); Anemia
- Myelofibrosis; Anemia
- Myelofibrosis
- Myelofibrosis Due to and Following Polycythemia Vera
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Myelodysplastic Syndromes
Approved drugs for the same conditions: Myelodysplastic syndromes · Myelofibrosis · Anemia · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DISC-0974" as an intervention, largest first.
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaPivotal-lookingRecruiting
Disc Medicine, IncIndustry
NCT05320198 · 150 participants (planned) · Start Jun 6, 2022 · Primary completion May 2027
Drug: DISC-0974 · For: Myelofibrosis; Anemia; Anemia; Myelofibrosis and 4 more
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 35 sites in all
Disc Medicine, IncIndustry
NCT05745883 · 55 participants · Start Apr 4, 2023 · Primary completion Oct 9, 2025
Drug: DISC-0974; Placebo · For: Chronic Kidney Diseases; Anemia of Chronic Kidney Disease
Sites: Los Angeles, California; Lone Tree, Colorado; DeLand, Florida · 13 sites in all
Disc Medicine, IncIndustry
NCT04999527 · 42 participants · Start Aug 10, 2021 · Primary completion Jun 30, 2022
Drug: DISC-0974; Placebo · For: Healthy Volunteer
Sites: San Antonio, Texas
Disc Medicine, IncIndustry
NCT07368972 · 21 participants (planned) · Start Feb 20, 2026 · Primary completion Oct 2026
Drug: DISC-0974; Placebo · For: Inflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.
Gangat N, Tefferi A · Am J Hematol 2025
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.
Chifotides HT, Duminuco A, Torre E, et al. · Curr Hematol Malig Rep 2025
- First-in-Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC-0974, an Anti-Hemojuvelin Antibody, in Healthy Participants.
Novikov N, Buch A, Yang H, et al. · J Clin Pharmacol 2024
- ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
Duminuco A, Chifotides HT, Giallongo S, et al. · Cancers (Basel) 2023
Also in development for Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BCD-131pegdarbepoetin betaPhase 31 trial
Biocad · Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
- SAL-0951SAL-0951 groupPhase 21 trial
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.